InDex's CEO Peter Zerhouni will present the Company at Pareto Securities' 10th annual Health Care Conference in Stockholm on September 5, 2019.Read more
- Company presentation
- InDex Pharmaceuticals on First North
- The share
- Interim Reports
- Annual Reports
- Press releases
- Capital Markets Day in Stockholm – April 25, 2018
- Financial calendar
- First North Certified Adviser
- IR contact
Ulcerative colitis is a chronic inflammatory bowel disease of unknown cause.
Symptoms include frequent stools, diarrhea, blood in stool, abdominal pain, fever, weight loss and anemia. Standard treatment includes anti-inflammatory, immunosuppressive and biological drugs.
A substantial percentage of patients with moderate to severe active ulcerative colitis will not respond to available therapies or will eventually develop tolerance to treatment.
Cobitolimod (Kappaproct, DIMS0150) is a potential new medication for patients with moderate to severe active ulcerative colitis.
Cobitolimod is a first in class treatment that provides a local anti-inflammatory effect which in clinical trials has shown to result in significant improvements of the major clinical symptoms.
Cobitolimod has very limited systemic absorption. This gives the drug a favorable safety profile, in sharp contrast to many approved treatments.